Tumor-induced Osteomalacia

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.

Author(s)

Gregory A. Poland, MD

Mary Lowell Leary Professor of Medicine, Infectious Diseases, Molecular Pharmacology, and Experimental Therapeutics, Mayo Clinic College of Medicine, Rochester, Minnesota; Director, Mayo Vaccine Research Group, Rochester, Minnesota; Director, Translational Immunovirology and Biodefense Program, Mayo Clinic, Rochester, Minnesota

Disclosures

Disclosure: Gregory A. Poland, MD, MACP, has disclosed the following relevant financial relationships:
Served as an advisor or consultant for: Novavax, Inc.; Merck & Co., Inc.; Avianax, LLC; GlaxoSmithKline; Novartis Vaccines; Emergent BioSolutions; Theraclone Sciences; MedImmune, Inc.; Liquidia Technologies, Inc.
Received grants for clinical research from: Novavax, Inc.; Merck & Co., Inc.; Wyeth Pharmaceuticals Inc.

William Curry, MD, MACP

Professor of Medicine
Department of Medicine
University of Alabama at Birmingham,
Birmingham, Alabama

Disclosures

Disclosure: William Curry, MD, MACP, has the following relevant financial relationships:
Advisor or consultant for: AstraZeneca; Bavarian Nordic; Dynavax; Eli Lilly and Company; Emergent Biosolutions; Exelixis; Genentech; Genevant Sciences, Inc.; GlaxoSmithKline; Janssen; Johnson & Johnson/Janssen Global Services LLC; Kentucky Bioprocessing; Medicago; Merck & Co.; Moderna; Regeneron; Sanofi Pasteur; Vyriad
Other: Chair of Safety Evaluation Committee: Merck Research Laboratories

processing....

For education on tumor-induced osteomalacia, visit https://www.medscape.org/viewarticle/948124_2

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred. The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Author(s)

Gregory A. Poland, MD

William Curry, MD, MACP

Tumor-induced Osteomalacia